Geneius Biotechnology

Executive Summary

Geneius Biotechnology is a clinical-stage biopharmaceutical company pioneering a novel class of autologous T-cell immunotherapies that re-educate patients' own T cells to recognize and eliminate tumor cells without genetic engineering. The company's technology leverages the natural ability of T cells to target multiple tumor-specific antigens, offering potential advantages in durability, safety, and accessibility over genetically modified cell therapies. Its lead programs are focused on EBV-associated lymphomas and solid tumors, addressing significant unmet medical needs in oncology. Currently, Geneius is advancing its lead candidate toward clinical trials and expanding its preclinical pipeline. The company's unique approach has attracted attention for its potential to broaden the therapeutic window and reduce manufacturing complexity. With a strong intellectual property portfolio and a seasoned management team, Geneius is well-positioned to deliver transformative therapies. Key upcoming milestones include the initiation of first-in-human studies and preclinical data readouts that could further validate the platform.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1/2 Clinical Trial for EBV-Associated Lymphoma80% success
• Q2 2026Presentation of Preclinical Data for Solid Tumor Program at Major Conference90% success
• H2 2026Strategic Partnership or Licensing Deal for Platform Technology30% success